The present study seeks to address the role of bioactive sphingolipid species and the enzymes regulating their metabolism and signalling in the development of resistance to BRAF inhibition by vemurafenib in BRAFV600E mutant colon cancer cells. Here, BRAF is linked to colonic neoplasm.